NIH selects Pittsburgh institute as leader for HIV/AIDS prevention efforts

June 30, 2006

Pittsburgh, June 30 - The University of Pittsburgh-affiliated Magee-Womens Research Institute is one of six institutions selected to lead HIV/AIDS prevention and treatment efforts by the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). Estimated at $285 million in funding for the first year, these leadership group awards represent the first step of a two-part restructuring process of the NIAID's clinical trials networks.

Sharon L. Hillier, Ph.D., professor of obstetrics, gynecology and reproductive sciences and of molecular genetics and biochemistry at the University of Pittsburgh School of Medicine, is principal investigator for the Pittsburgh consortium, which has been designated to lead the Microbicide Trials Network (MTN). The mission of the MTN is to develop new drugs and drug delivery systems to prevent HIV and its spread.

"The leading method of transmission for HIV/AIDS infection today is heterosexual intercourse," said Dr. Hillier, who also is a senior investigator at the Magee-Womens Research Institute. "And in many parts of the world, a woman's single biggest risk factor for the acquisition of HIV is being married. Currently, women have no way to protect themselves except condoms, and women do not control condom use."

Dr. Hillier's group is involved in evaluating drugs for the prevention of sexually transmitted infections such as HIV. Clinical trials have been designed to support the licensing of new agents for the prevention of HIV that could be used by women at risk of infection both in the U.S. and internationally. NIAID's decision to fund the MTN reflects a growing recognition that novel approaches to prevention will be needed to slow the epidemic of AIDS.

"Pittsburgh proved its scientific worth more than 50 years ago when the development of the Salk vaccine signaled an end to the scourge of polio," said Arthur S. Levine, M.D., senior vice chancellor, health sciences, and dean of the University of Pittsburgh School of Medicine. "Perhaps soon we can point to efforts here that will lead to a similar end to the deadly spread of HIV/AIDS."

More than 4 million new HIV infections yearly, the majority of which are sexually transmitted, make the prevention of sexual transmission of HIV a top public health priority. The Pittsburgh-based MTN will focus on the identification and development of topically applied drugs called microbicides in a form that is acceptable both for the women who will use them and for their partners.

"The global HIV epidemic is spreading among women and young girls at an alarming rate," said Dr. Nicholas Hellmann, acting director of HIV, TB and reproductive health programs at the Bill & Melinda Gates Foundation. "By accelerating the development of new prevention methods such as microbicides, we have an opportunity to save millions of lives."

Dr. Hillier explained that with microbicides, drug agents proven to have activity against HIV can be applied directly to areas of the body where the infection takes place.

"While the development and testing of topical microbicides for prevention of HIV might seem to be straightforward, these products need careful evaluation because they will be used repeatedly with each act of intercourse over many years," said Dr. Hillier. "This requires a subtle balance between toxicity and effectiveness, ease of use and, ultimately, cost."

Several large clinical trials are currently ongoing to test the safety and efficacy of a number of microbicidal preparations. The MTN designation will continue this international effort with support for these ongoing clinical trials in several countries including Africa and India. Locations of sites for new clinical trials, along with finalized budgets, will be released when the second phase of the funding plan is available from NIAID.

"We are pleased and proud to receive this recognition from the National Institutes of Health," said James M. Roberts, M.D., director of the Magee-Womens Research Institute. "To be able to bring a project of this magnitude to Pittsburgh is consistent with our commitment to improving the health of women and their infants around the world."
In addition to Dr. Hillier, University of Pittsburgh faculty members involved in the MTN project include John W. Mellors, M.D., professor of medicine, and chief of the division of infectious diseases and director of the HIV/AIDS program at the University of Pittsburgh Medical Center; Charlene Dezzutti, Ph.D., associate professor of obstetrics, gynecology and reproductive sciences and molecular genetics and biochemistry; Bernard J. Moncla, Ph.D., research associate professor, obstetrics, gynecology and reproductive sciences; and Lisa Cencia Rohan, Ph.D., assistant professor, pharmaceutical sciences and obstetrics, gynecology and reproductive sciences. Research partners for the MTN also come from 20 other leading universities.

University of Pittsburgh Medical Center

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to